PRINCETON, N.J., Dec. 22, 2017 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) in response to the New…Original Article
Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla (AG200-15) for the Prevention of Pregnancy
